AU629237B2 - Recombinant fusion proteins for altering hormone secretion - Google Patents

Recombinant fusion proteins for altering hormone secretion Download PDF

Info

Publication number
AU629237B2
AU629237B2 AU40761/89A AU4076189A AU629237B2 AU 629237 B2 AU629237 B2 AU 629237B2 AU 40761/89 A AU40761/89 A AU 40761/89A AU 4076189 A AU4076189 A AU 4076189A AU 629237 B2 AU629237 B2 AU 629237B2
Authority
AU
Australia
Prior art keywords
fusion protein
protein
lhrh
gene
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU40761/89A
Other versions
AU4076189A (en
Inventor
Scott C. Chappel
Noreen P. Nugent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of AU4076189A publication Critical patent/AU4076189A/en
Application granted granted Critical
Publication of AU629237B2 publication Critical patent/AU629237B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

OPI DATE 23/03/90 APPLN. ID 40761 89
PCT
AOJP DATI6r4/i 2 PcUNUdZR PCT/EP89/01013
INTERNATIONAL
Y (PCT) (51) Internatior.al Patent Classification (11) Internatioal Pulication Number: WO 90/02187 C12N 15/62 C12N 15/16 Al A61K 39/385 (43) International Publication Date: 8 March 1990 (08.03.90) (21) International Application Number: (22) International Filing Date: 2 Priority data: 246,558 30 Augus PCT/EP89/01013 29 August 1989 (29.08.89) (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, KR. LU (European patent), NL (European patent). NO. SE (European patent).
Published With international search report.
Before the expiration of the time limit Jor amending the claims and to be republished in the event 9f the receipt of amendments.
t 1988 (30.08.88) (71) Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; John B. Gorsiraweg 6, Curacao (AN).
(72) Inventors: CHAPPEL, Scott, C. 39 Hancock Street, Boston, MA 02114 NUGENT, Noreen, P. 38 Westgate Road, Framingham, MA 01701 (US).
(74)Agent: RITTER, Stephen, David; Mathys Squire, Fleet Street, London EC4Y lAY (GB).
(54)Title: RECOMBINANT FUSION PROTEINS FOR ALTERING HORMONE SECRETION I T (57) Abstract H 3 N L I d Coo A recombinant fusion protein, resulting from the expression, of two genes regulated by single promoter, having the effect of altering hormone secretion when administered in a therapeutically effective dose. One gene codes for the production of a highly antigenic, hydrophilic protein, such as hepatitis B surface antigen, and the other gene codes for a peptide which alone is not substantially antigenic, such as luteinizing hormone releasing hormone.
Bam Ava Ava Xba Ava I I I I I HbSA
I
L Bam Ava Ava Xba 1 1 I I HbSA+ LHRH I .I r tl PCT/EP89/01013 WO 90/02187 suggested to use non-antigenic peptides in such a fusion protein i nr or t- Ih hl nrlii 4-V 'n r r F 4 4- 4 -4- WO 90/02187 PCT/EP89/01013 RECOMBINANT FUSION PROTEINS FOR ALTERING HORMONE SECRETION Field of Invention This invention relates to the production of fusion proteins produced by recombinant DNA technology and used as active immunogens against peptides which are not inherently antigenic.
By combining the gene for a highly antigenic protein, such as the hepatitis surface antigen (KBsAg), and the cDNA encoding for a protein, portion of a proteinj r-peptide which is not inherently antigenic, a fusion protein may be expressed. Following injection of this highly antigenic fusion protein, polyclonal antibodies are produced that are directed against both the highly antigenic protein and the protein of interest. Thus, this technology provides a method to immunoneutralize endogenously produ:-[', hormones and could be used to induce an infertile state or inhibit the hormone dependent growth of rapidly multiplying tissue.
Background of the Invention As a result of the pioneering work of Guil?'min, Schally and coworkers during the late 1960's, it has become evident that the hypothalamic decapeptide, luteinizing hormone releasing hormone (LHRH) is intimately involved in the initiation and maintenance of reproductive competence in all mammals. Disruption or 'destruction of neuronal pathways involved in the synthesis of LHRH or its transport to the capillary network that provides humoral communication between the hypothalamus and pituitary results in a I SUBSTITUTE
SHEET
WO 90/02187 PCT/EP89/01013 reduction in gonadotropin synthesis and release and infertility (Kalra and Kalra, Endocrine Reviews 4:311, 1983).
Similarly, reductions in LHRH-pituitary interactions may be elicited through the administration of long-acting competitive antagonists of LHRH. These synthetic peptides bind to the pituitary LHRH receptor but do not stimulate post-receptor intracellular activities. Due to their unusually long receptor occupancy, caused by their resistance to proteolytic inactivation, these peptides induce a state of pituitary insensitivity to LHRH due to down regulation of LHRH receptor number. This pharmacologic reduction in pituitary stimulation by LHRH antagonists results in a reduction in gonadotropin release and infertility (Labrie et al [eds] LHRH and its analogs. Amsterdam: Elsevier Scientific Publishers. 1984).
Another method employed to disrupt LHRH-pituitary interactions has been the production of antibodies against LHRH.
Active LHRH immunization has been accomplished in a number of species including the rat (Fraser et al; J. Endocrinology 63:399, 1974), rabbit (Arimura et al; Endocrinology 93:1092, 1973), ewe (Clarke et al: J. Endocrinol 78:39, 1978) and rhesus monkey (Chappel et al; Biol. Reprod. 22:333, 1980). In all species, active immunization against LHRH results in a loss of reproductive function characterized by low serum concentrations of gonadotropins and gonadal steroids and impairments in gametogenesis. Due to the extremely short half-life of LHRH in an animal (less than five minutes), most active immunization has been performed with LHRH conjugated to much larger molecules., such as bovine serum 'SUBSTITUTE SHEET THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A recombinant fusion protein, resulting from the expression of two genes regulated by a single promoter, wherein the first of said genes codes for the rI rn hiin of a hiahly antigenic, hydrophilic protein nl WO 90/02187 PCT/EP89/01013 albumin and presented in Freund's Complete Adjuvant, to induce an immune response. Immunoneutralization of hypothalamic LHRH can be employed as a routine procedure to induce an infertile state characterized by low circulating levels of gonadotropins and S. gonadal steroids and anovulation or azospermia.
The production of antibodies against LHRH by active immunization is uncomfortable, if not painful, to the animal.
Although this method would induce a state of infertility and reduce behavioral heat (due to low circulating gonadal steroids) it could not be employed as a pet contraceptive.
There is a serious over-population of cats and dogs in the United States which is of great concern to the general public, animal welfare organizations, veterinarians, and health officials.
In the feline population, the reproductive rate has been reported to be almost twice the rate at which homes become available for these animals (Shreider and Vaida. J Am Vet Med Assoc. 166 481, 1975). To halt the growth of the feline population, approximately 88% of reproductively competent females should be spayed (Nassar and Masier, Am J Vet Res. 43:167, 1982). Approximately 20% of the dog population in the United States passes through an animal shelter each year and of that, approximately 80% of these animals are destroyed. The cost of impounding and destroying unwanted cats and dogs ranges from $125 to $500 million per year (Am.
Humane Society: Proceedings on Ecology of the Surplus Cat and Dog Problem).
SUBSTITUTE
SHEET
luteinizing hormone releasing hormone protein is expressed having antigenic characteristics.
DNA according to claim 8 or 9 wherein said second gene is inserted into one or more regions of said WO 90/02187 PCT/EP89/01013, At present, the only solutions to the problem of unwanted pregnancies in the dog and cat population are complete confinement and surgical gonadectomy. Neither method may be considered effective as a means of birth control. confinement does not reduce behavioral problems associated with heat and neutering clinics do not reach sufficient numbers of animals to alleviate the over-population problem. Costs of skilled professionals to perform the surgery, anesthesia, antibiotics and postoperative care are beyond the means of many pet owners.
It is an object of the present invention to provide a recombinant fusion protein or vaccine which provides an effective, safe, available and reversible means of fertility control. A vaccine that is easily administered is likely to supplant surgical sterilization while providing an effective contraceptive for dogs, cats and other mammals.
Pregnant cows typically do not exhibit an attractive feed to meat conversion since the developing fetus requires great nutritional requirements. As a result, feed loL owners generally pay substantially less for a cow in which the pregnancy status is unknown or unconfirmed. A certain percentage of cows enter the feed lot pregnant and the fetus represents waste. Thus, a method to induce an infertile state in cows 6-10 months prior to shipment is considered to be a viable, valuable product. If the farmer could guarantee that his cattle are "barren" he could command a higher price for his animals.
I
SUBSTITUTE
SHEET
CCI
WO 90/02187 PCT/EP89/01013 6 It is, therefore, another object to provide a recombinant, injectable product which would result in inhibition of ovulatory cyclicity in feedlot heifers.
There are many examples of human hormonally-mediated tissue hyperplasia. In the male, it is well known that prostatic carcinoma (BPH) is dependent upon testicular testosterone for continued growth. It would be advantageous to reduce serum levels of gonadotropins to inhibit gonadal steroid secretion and thus induce involution of hyperplastic tissue. It has recently been reported that a long-acting LHRH antagonist may be used in the treatment of prostatic hyperplasia (Peters and Walsh, New England Journal Medicine 317:599, 1987). The mechanism of action of this treatment is the inhibition of LH and FSH secretion by down-regulation of pituitary LHRH receptors. This results in an inhibition of gonadotropin secretion which causes a fall in testosterone production. A reduction in serum testosterone causes a regression of the prostatic hyperplasia. The authors note, however, that inhibition of LH secretion as elicited by injection of an LHRH antagonist would be required for prolonged periods of time, thus necessitating repeated administration.
It is yet another object of the present invention to avoid injections of LHRH antagonists to inhibit gonadotropin secretion, immunoneutralization of endogenous LHRH.
It is still a further object of the present invention to provide a method to make any substantially non-antigenic peptide highly immunogenic, preferably without the necessity of use of adjuvants such as Freund's Complete Adjuvant.
SUBSTITUTE
SHET
WO 90/02187 PCT/EP89/01013 FIG 1 Summary of the Invention In accordance with the principles and objectives of the present invention, there are provided methods for creating fusion proteins that may be employed as potent immunogens. Specifically, the present invention provides a recombinant fusion protein, resulting from the expression of two genes regulated by a single promoter, wherein the first of said genes codes for the production of a highly antigenic, hydrophilic protein and the second of said genes codes for a peptide which alone is substantially non-antigenic, or for a portion of such a peptide. The present invention further provides DNA encoding for the fusion protein comprising said two genes, a transcriptional initiation region, a promotor and an expression vector, said DNA capable of transforming mammalian cells to express the fusion protein. Ideally this i 2 0 I e :i VF PCT/EP89/01013 WO 90/02187 FIG 2 o ee* WO 90/02187 PCT/EP89/01013 Ii Summary of the Invention In accordance with the ri es and objectives of the present invention, are provided methods for creating fusion prot that may be employed as potent immunogens. Ideally, this method of the present invention employs molecular biology techniques to fuse cDNAs together, and to place them into a eukaryotic expression vector for the production of unique fusion proteins.
The majority of this fusion protein is a highly antigenic and potent immunogen. It should have substantial hydrophilicity.
Good examples of such immunogens are coat proteins such as the hepatitis B surface antigen. An oligonucleotide coding for the peptide of interest, against which it is desired to raise antibodies, such as the luteinizing hormone releasing hormone molecule, is placed in one or more regions of the protein, preferably in the one or more regions having the highest hydrophilicity.
Injection of the resultant protein, most preferably an LHRH-HBsAg fusion protein, in therapeutically effective concentration, will result in the development of antibodies against the entire molecule. A portion of these antibodies will be directed against the peptide of interest. Most preferably, when the peptide is LHRH, sufficient titres of antibodies against LHRH will be provided thereby preventing hypothalamic-pituitary communication and inducing an infertile state. This immunogen may also be advantageously employed in a variety of commercial or therapeutic settings including i.n animal anti-fertility vaccine and treatment for benign prostatic hypertrophy.
SUBSTITUTE
SHEET
I^
II
III
WOo 90/02187 PCT/EP89/01013 WO 90/02187 PCT/EP89/01013 The fusion proteins of the present invention are sufficiently immunogenic so as'to preclude the necessity of use of adjuvants or multiple injection, neither of which are well tolerated by the subject.
Brief Description of the Drawings Figure 1. Illustrates the insertion of gonadotropin releasing hormone sequences within the exposed hydrophilic region of HBsAg protein. At the top is a diagram of the HBsAg protein in which the site containing the LHRH decapeptide is stippled. Below that is the Aval site along the cDNA that codes for HBsAg in which the cDNA for LHRH is ideally inserted. The figure at the bottom represents a viral coat particle with LHRH inserted between the coat protein sequences.
Figure 2. Illustrates a synthetic DNA linker that will be inserted into the Aval site of the HBsAg (see Fig. This linker provides a flexible insertion site for oligonucleotide sequences after amino acid 119 (glycine) of the HBsAg. It results in the insertion of three amino acids before the resumption of the HBsAg sequence at the proline residue (position 120). The LHRH fragment is preferably inserted between the SmaI and BqlII site of the linker. Addition of the linker will maintain the proper reading frame (see Fig. 3).
SUBSTITUTE
SHEET
PCT/EP89/0101 3 WO 90/02187 FIG 4 Metalothionein promoter i WO 90/02187 PCT/EP89/01013 8 FiGure 3.
Figure 4.
Shows the nucleotide sequence for the LHRH peptide to be inserted in the synthetic linker within the HBsAg cDNA.
To maintain the proper reading frame, two additional nucleotides (GG) have been added to the 3' end of the oligonucleotide which will add a glycine (GGG) immediately following the inserted LHRH peptide and maintain the proper reading frame. Note the GG added to the 3' end to maintain the proper reading frame when inserted into the synthetic DNA linker (Figure We have also added the BglII overhang for proper insertion into the cut linker.
Diagrams the scheme used to insert HBsAg-LHRH fusion into mouse metallothionein promoter (CL28 vector) and subsequent insertion of the BPV genome. The plasmid EPV-HL is advantageously used to transform C127 cells.
Detailed Description of the Invention and Best Mode The gene encoding for the hepatitis B surface antigen has already been cloned and expressed (Hsiung et al., J. Mol.
Appl. Gen. 2:497, 1984). This gene is advantageously expressed in our mammalian expression system. The DNA encoding the coat protein was cloned into the mouse metallothionein gene, just a few base pairs from the site of transcription initiation. All of the signals that regulate the expression of the inserted gene (for coat protein) in mammalian cells are supplied by the mouse gene, whose coding sequences and poly A addition signals lie downstream from the insert. The surface antigen protein is secreted ibto the SUBSTITUTE
SHEET
i WO 90/02187 PCT/EP89/01013 medium where it is found in the form of particles. The recombinant product surface antigen without nuclear material) has been shown to be highly immunogenic in guinea pigs.
From the DNA sequence, the amino acid sequence of the hepatitis antigen was determined. This sequence was analyzed for the region of the molecule that would be expected to have the most hydrophilic properties. Into that region (identified by the AvaII site in Figure 1) was cloned a short oligonucleotide sequence that provides unique cloning sites (Figure Into this region, cDNA sequences encoding for specific proteins may be inserted either by blunt end ligation at a unique Smal site or at the BqlII site (see Figure 2).
Using the published structure of the hypothalamic gene (Seeburg and Adelman: Nature 311:666, 1984: Figure 3) but modified as described above, the oligonucleotide encoding LHRH was s-nthesized on an Applied Biosystems 380-A automated DNA synthesizer using the solid phase synthetic methods developed by Caruthers et al (Genetic Engineering 4:1-17, 1982). The oligonucleotide was cleaved from the solid support using concentrated am.nonium hydroxide. Purification was achieved using preparative gel electrophoresis. The purified oligonucleotide was polynucleotide kinase and analyzed by gel electrophoresis for size and purity.
The LHRH oligonucleotide was inserted into the SmaI and BagII cloning site by the following method: The LHRH oligonucleotide was synthesized (as shown in Figure 3) to contain a 3' blunt end and a 5' CTAG overhang. Folloving digestion of the HBsAg DNA (containing the synthetic insert) with Sma I and BqlII, the LHRH SSUBSTITUTE SHEET I I INTERNATIONAL SEARCH REPORT Internatlonal Apolicatlon No PCT/EP 89/01013 1. CLASSIFICATION OF SUBJECT MATTER (It several clasinc3ilon symbols aocly. Indicate all) Accotding to Intlrnatlonal Patont Classlicallon (IPC) or to both National Clasaificatlon and IPC C 12 N 15/62, 15/16 A 61 K 39/385 WO 90/02187 PCT/EP89/01013 DNA was inserted. The resultant construction was named HBsAg- LHRH. Synthetic BamHI linkers were added to each terminus of the HBsAg-LHRH cDNA and inserted into the vector CL28/Bam in the proper orientation. CL28/Bam obtained from Dr. Dean Hamer (at the NIH) contains a 3.8 kbp mouse DNA fragment that includes the entire metallothionein gene, including upstream control elements, inserted into the EcoRI site of the bacterial vector pBR322.
CL28/Bam is a derivative of pJYMMT(E) (Hamer, Dean et al, J. Mol.
Appl. Genet. 1, 4, 273-288 (1982)) which is identical to pJYMMT(E) except for the removal of the SV40 sequences. A unique BcrlII site located just after the transcriptional initiation region of the mouse gene allows the insertion of foreign genes as BamHI fragments which have the same 5' overhang (GATC) as the cut BglII site. Following the insertion of the HBsAg-LHRH fusion gene into CL28/Bam and endonuclease verification of orientation by the proper restriction pattern (with respect to the murine promoter) the entire genome of Bovine Papilloma virus (BPV) was inserted as a 7.B kbo BamHI-Sall fragment. The final construction was verified by examination of diagnostic restriction enzyme digestion patterns on both agarose and polyacrylamide gels. A schematic representation of this method is provided in Figure 4.
Thus, the resultant hepatitis B surface protein contained an LHRH sequence within a hydrophilic region of the !I molecule.
To produce a cell line that expresses the fusion HBsAg/LHRH protein, 10pg of the purified BPV-HBsAg-LHRH cDNA was added to 0.5 ml of a 250mm CaCl 2 solution containing 10g salmon f SUBSTITUTE SHEET international Aollicatlon No. PCT/EP 89/01013 III, DOCUMENTS CONSIDERED TO LE RELEVANT (CONTINUED FROM THE SECOND SHEET) Category Citation of Docunmnt, with indicatlon., w.e saproonate. of the reivlt passage Relevant to Claim No I y FD nI 111 f z trci TItr', i TTI- WO 90/02187 PCT/EP89/01013 sperm DNA as a carrier. The mixture was bubbled into 0.5ml of 28mM NaC1, 50mM HEPES and 1.5mM sodium phosphate. The calcium phosphate precipitate was allowed to form for 30-40 minutes at room temperature.
Twenty-four hours prior to transfection, 5 x 105 mouse C127 cells were placed into 100mM petri dish. Immediately before adding the exogenous DNA, cells were fed with fresh medium (Dulbecco's modified Eagle's medium plus 10% fetal calf serum). One ml of calcium phosphate precipitate were added to each dish and the cells incubated for 6-8 h at 37"C.
Medium was aspirated and replaced with 5ml of 20% glycerol in phosphate buffered saline (pH 7.0) for 2 min. at room temperature. Cells were washed with phosphate buffered saline, fed with 10ml medium and incubated at 37'C. After 20-24 hours, medium was changed and cells refed every 3-4 days.
After 14-21 days, foci of transformed cells, characterized by their altered morphology, were identified and transferred to T-25 flasks to begin line expansion. Medium obtained from the cell lines was tested for presence of HBsAg and LHRH immunoactivity. Tissue culture medium was clarified by low speed centrifugation and HBsAg particles were sedimented at 42,000 rpm (200,000 xg) for 4 hours. Pellets were resuspended in a small volume of phosphate-b'ffered saline and assayed along with starting material and supernatants for HBsAg activity with a commercial radioimmunoassay (RIA) purchased from Clinical Assays, Inc. The culture medium supernatants and resuspended pellets were analyzed for LHRH immunoactivity with a radioimmunoassay utilizing LHRH antiserum SUBSTITUTE
SHEET
ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. PCT/EP 89/01013 ZAI -7 C WO 90/02187 PCT/EP89/01013 purchased from Arnel Antibodies, Inc. The LHRH for iodination and the reference preparation were purchased from Sigma Fine Chemicals, Inc., and the insoluble protein A (to pellet antigenantibody complexes) was obtained from Sigma Fine Chemicals, Inc.
Following these procedures, cell lines expressing the fusion protein were produced and readily identified by standard screening methods. With a few milligrams of purified material, the appropriate dose to elicit an infertile state in male rabbits or other animals may be determined with a titration type procedure. For example, male rabbits injected with 0.5, 1 or 5 mg of the protein coupled with blood sample collection will allow determination of serum gonadotropin and testicular steroid levels as well as anti-LHRH antibody titres. Similarly, appropriate boosting intervals may also be determined.
From the foregoing, those skilled in the art will raadily determine that numerous modifications can be made to the fusion genes and gene products such as the selection of the antigenic gene or the protein gene whose activity is to be immunologically suppressed, without departing from either the spirit or scope of the present invention. For example, highly immunogenic proteins other than HBsAg may be used, such as other hydrophilic coat proteins or the hepatitis B core antigen. Furthermore, those skilled in the art will understand that peptides other than LHRH may be used. While a similar method has been reported for presenting antigenic epitopes to the immune system, in Australian patent 69792/87, antigenic apitopes are always used, such as viral, bacterial or protozoan epitopes. It has not before been SUBSTITUTE
SHEET
I wWO 90/02187 s~ JI PCT/EP89/01013 suggested to use non-antigenic peptides in such a fusion protein in order to be able to induce the production of antibodies against such peptides without the disadvantages of prior art haptenization techniques.
Examples of substantially non-antigenic peptides are peptides which do not substantially differ in structure across species or any other peptide or protein which, when injected into a foreign animal, does not cause any substantial titre of antisodies to be raised against it. Besides LHRH, there may be mentioned growth hormone releasing hormone, adrenocorticotropin hormone, parathyroid hormone, inhibin, and subunits of gonadotropins. Portions of or slightly modified versions of such peptides may also be used.
SUBSTITUTE
SHEET

Claims (9)

  1. 2. A fusion protein according to Claim 1 wherein the fusion protein is highly antigenic and causes the production of antibodies which include antibodies against said substantially non-antigenic peptide.
  2. 3. A fusion protein according to Claim 1 or 2 wherein said peptide comprises a hormone and the antibodies produced can immuno-neutralize the same hormone endogenously produced.
  3. 4. A fusion protein according to any one of Claims S 1-3 wherein said highly antigenic, hydrophilic protein is hepatitis surface antigen. -0 5. A fusion protein according to any one of Claims 1-4 wherein the second gene encodes for a protein having hormonal activity substantially similar to the activity of an endogenously produced hormone.
  4. 6. A fusion protein according to Claim 5 wherein said second gene encodes for luteinizing hormone releasing hormone.
  5. 7. A fusion protein according to any one of claims 1-6 wherein said second gene is inserted into one or more S regions of said first gene, each of said regions encoding a highly hydrophilic region of said protein.
  6. 8. DNA encoding for the fusion protein of any one of Claims 1-7 comprising said two genes, a transcriptional initiation region, a promotor and an expression vector, said DNA capable of transforming mammalian cells to express the fusion protein.
  7. 9. DNA according to Claim 8 comprising DNA encoding for HBsAg-LHRH protein fused ith a mouse metallothionein promoter and a bovine papilloma virus 39 genome in proper sequence and reading frame whereby a AL1,14;~ luteinizing hormone releasing hormone protein is expressed having antigenic characteristics. DNA according to claim 8 or 9 wherein said second gene is inserted into one or more regions of said first gene, each of said regions encoding a highly hydrophilic region of said protein.
  8. 11. A recombinant fusion protein according to claim 1 substantially as hereinbefore described.
  9. 12. DNA according to claim 8 substantially as hereinbefore described. DATED: 5 June 1992 PHILLIPS ORMONDE FITZPATRICK Attorneys for: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. e *0 *o*
AU40761/89A 1988-08-30 1989-08-29 Recombinant fusion proteins for altering hormone secretion Ceased AU629237B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24655888A 1988-08-30 1988-08-30
US246558 1988-08-30

Publications (2)

Publication Number Publication Date
AU4076189A AU4076189A (en) 1990-03-23
AU629237B2 true AU629237B2 (en) 1992-10-01

Family

ID=22931196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40761/89A Ceased AU629237B2 (en) 1988-08-30 1989-08-29 Recombinant fusion proteins for altering hormone secretion

Country Status (9)

Country Link
EP (1) EP0396653A1 (en)
JP (1) JPH03502584A (en)
AU (1) AU629237B2 (en)
DK (1) DK106590A (en)
FI (1) FI902151A0 (en)
GR (1) GR1000321B (en)
IL (1) IL91462A0 (en)
WO (1) WO1990002187A1 (en)
ZA (1) ZA896628B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0448513A3 (en) * 1990-03-21 1991-12-27 Japat Ltd Process for production of peptidylglycine alpha-hydroxylating monooxygenase and use thereof
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
JPH05339295A (en) * 1991-12-05 1993-12-21 Agency Of Ind Science & Technol Preparation of antibody
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
ATE286511T1 (en) * 1999-02-17 2005-01-15 Pfizer Prod Inc FUSION PROTEINS WITH CARRIERS THAT INDUCE A DOUBLE IMMUNE RESPONSE
EP1303533A2 (en) 2000-05-05 2003-04-23 Aphton Corporation Chimeric peptide immunogens, their preparation and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963691A (en) * 1974-10-07 1976-06-15 Merck & Co., Inc. Synthetic antigens of luteinizing hormone releasing hormone
GB8314362D0 (en) * 1983-05-24 1983-06-29 Celltech Ltd Polypeptide and protein products
ATE70308T1 (en) * 1984-09-12 1991-12-15 Chiron Corp HYBRID PARTICLE IMMUNOGENS.
IL78775A (en) * 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
AU5993186A (en) * 1985-06-04 1987-01-07 Biotechnology Research Partners Limited Autoantigen vaccines
GB8525615D0 (en) * 1985-10-17 1985-11-20 Hoffmann La Roche Polypeptides

Also Published As

Publication number Publication date
DK106590D0 (en) 1990-04-30
ZA896628B (en) 1991-04-24
GR890100540A (en) 1990-08-22
WO1990002187A1 (en) 1990-03-08
IL91462A0 (en) 1990-04-29
DK106590A (en) 1990-04-30
JPH03502584A (en) 1991-06-13
FI902151A0 (en) 1990-04-27
AU4076189A (en) 1990-03-23
GR1000321B (en) 1992-06-25
EP0396653A1 (en) 1990-11-14

Similar Documents

Publication Publication Date Title
Jones et al. Phase I clinical trial of a World Health Organisation birth control vaccine
US6087352A (en) Use of Zeranol to modulate reproductive cycles
CA2255888A1 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
US20210054041A1 (en) Glycoprotein Hormone Long-Acting Superagonists
AU2017431494A1 (en) Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof
Zhang et al. Development of recombinant ovalbumin-luteinizing hormone releasing hormone as a potential sterilization vaccine
WO1991016922A1 (en) Analogs of glycoprotein hormones having altered immunological characteristics, efficacy and/or receptor specificity
AU629237B2 (en) Recombinant fusion proteins for altering hormone secretion
JP3959746B2 (en) Improved peptides, immunogenic compositions and vaccines or pharmaceutical formulations, methods of immunizing animals against LHRH hormones, and LHRH tandem repeat peptides and their use as vaccines
CA1330420C (en) Compositions containing growth hormone peptide fragments
JPH05500654A (en) Contraceptive vaccine based on cloned zona pellucida gene
US20020107187A1 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
JPH03503403A (en) biologically active molecules
CN100522994C (en) Discrimination between GnRH-I and GnRH-II
JP2899534B2 (en) Method of inducing superovulation in cattle
JPS63503141A (en) How to regulate reproductive function in animals
McCauley et al. Manipulation of endogenous hormones to increase growth of pigs
JP2000508293A (en) Novel peptide useful for promoting FSH action
US5212156A (en) Srif-related peptides and uses thereof
Barkley Evidence for maternal regulation of progesterone production at midpregnancy in the mouse
Scaramuzzi et al. The implications of immunological techniques for the improvement of production efficiency in pigs.
AU738528B2 (en) Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof
CN115991792A (en) Long-acting recombinant LH fusion protein and preparation method and application thereof
Chang THE REGULATION OF REPRODUCTION IN CATTLE BY AN ANTIESTROGEN, OR ACTIVE IMMUNIZATION AGAINST PROSTAGLANDIN F (2ALPHA) AND OVARIAN STEROIDS
Cytoskeleton Hsp90 and S1.(A) SDS-PAGE analysis of S1 (10 M) and/or Hsp90 (1 M) interacting with UNC-45 (1 M) at 30 C for 30 min.(B) The aggregation of S1 (1.0 M) at 43 C was measured by light scattering (320 nm)(11) with no additional protein (solid circles), 2.0 M bovine serum albumin (open circles), 0.5 M UNC-45 (squares), 1.0 M UNC-45 (diamonds), or 2.0 M UNC-45 (triangles).